BeiGene
BGNE
$187.49
Share price
0.29%
Change (1 day)
-2.15%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Total assets
Total assets on the balance sheet as of September 2023 : $5.52 B
According to BeiGene 's latest financial reports the company's total assets are $5.52 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
BeiGene - Total assets on balance sheet (from 2014 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2022-12-31 | $6.37 B | -26.22% |
| 2021-12-31 | $8.64 B | 54.37% |
| 2020-12-31 | $5.60 B | 247.38% |
| 2019-12-31 | $1.61 B | -28.33% |
| 2018-12-31 | $2.24 B | 114.98% |
| 2017-12-31 | $1.04 B | 157.87% |
| 2016-12-31 | $0.40 B | 247.55% |
| 2015-12-31 | $0.11 B | 117.76% |
| 2014-12-31 | $53.62 M | 354.49% |
| 2013-12-31 | $11.79 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $2.05 B | -62.77% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $30.46 M | -99.45% | 🇺🇸 USA |